{"name":"Domain Therapeutics Australia Pty Ltd","slug":"domain-therapeutics-australia-pty-ltd","ticker":"","exchange":"","domain":"domainaustraliapty.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSU1nZ0VqM3RfRGppZVpmaW9IaWEtSXFzMDVLc3QybFZPQnMyb2szcm0xeDB2UGNJeVQ1dUpEMlU4Sy0tamtsQ0lJV0Z4VGc4WFdkcjJTN0VJa1RhRXB6YWNNempmZURoRE95Y05ocktOeEFOeHdtcHkwT3d5NnYwTmNDNjNDVUFERkRNTk9BOVp6cU1SSmk0YUNKQQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key - openPR.com","headline":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOWmdoSVZTdVhrc3VVWXlRWHdpT2l0Y3ZYSDBld0V5VlEwX1lEenNkNlBBMEI0X19WVVYxdGFuOWY3VzlLek5zbXBmVGVZMFFHamp5bFB0dmctLWs2RTRUQVM3eXFlLURMMW1kcUdvUllvUDVqRjJQR3ppRzI0SXRsZExxSGdiSFNaeGJpOGpqXzIwSEFUQ0dxdko5RFBUcWJUdHNzaWFiM2FaQ2lGdlBrVTV2V2RVaXgwRDNuX01ZdmFaQ05PNDZqdjRrT2hYaWxyZFk4d1FNUFdkQTlUYUZEU2sxaGh5ZkQxeTlTQ1dsQm1HQUhnX2JHTWE2Yw?oc=5","date":"2026-03-05","type":"trial","source":"Barchart","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNVFZEYXR4NTJmWG0wMW5xenp3ZVN2VjlMalFBSk42Yjc1Q3dXRjI3NDIxVUFBSmtscjNNT0xoUC0wSmZXU3Z2ZjJ0RERNMFVlOGhtdVVtTk9FTk43QTFiNjhyWFZ1cmpIOFFtTHFkR3dkbVAwWHFwZTc0emdiMnI1cXExYmFsb0I1QkhLWFVBLXI?oc=5","date":"2026-01-12","type":"pipeline","source":"Manufacturing Chemist","summary":"Domain Therapeutics rebrands as Kainova Therapeutics to advance GPCR-focused clinical pipeline - Manufacturing Chemist","headline":"Domain Therapeutics rebrands as Kainova Therapeutics to advance GPCR-focused clinical pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECL","headline":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOUWhFTHZubXNVc0c5MWZmNnNoaGxIbjczbWZTcjdsRFBEQndfcjB4Q3lTY2RYSkhnSFJpNFJCcVpoM20yd1lCbTdzOUJJTjQ4M1hqUmRMWlV1aW1ZbzlycVFXX2IzYm1EdS0wUWhVbU1YVDhpQ0RMUVBaTTF5dUlOYjQzLTNhaWh6MndoUHMwT3ZDRHJtSGRHNC1tSEswSG1SaV9J?oc=5","date":"2025-10-28","type":"trial","source":"pharmatimes.com","summary":"Domain Therapeutics begins patient dosing in phase 1/2 trial of DT-7012 - pharmatimes.com","headline":"Domain Therapeutics begins patient dosing in phase 1/2 trial of DT-7012","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOM0Nsc1pfak51TEh5Wlk1MzNBMm93UnQ4aEhaMHdiejZLNFlic0RNQmhBS2p2N0hMY2dRX0kxcGw3cVIxZUhoWHRPamF2WmQwZzhJcVlvcWNHbzR0aDBwNVhHUEdvOGgzU2g1dlpnM0VaRExyeGl4SGRoM09MVjJPaGFhdHR6VWtvaUZUNmF6WnlCWnJNdXY5ZEY3WDJORHdheldrNXJQRjBON2dVdVlGc3RMbWJFVVZzMU5BRm5td2tfZnpoam9QSHlDemlOSks2dmww?oc=5","date":"2025-10-09","type":"deal","source":"BioPharma APAC","summary":"Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2 - BioPharma APAC","headline":"Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPVHZOVnp3bUl1THE5aVdPQmFjU1VzSy1Ub1A1YzBzVVhLdDFtUkNJNXo3RU1Wbm1idkNCQ0FvNXRUWl84dVJ4cnBLOFFmNVM0Q1dza1h6Z2ZDd0IxWmNQMXlQcVctcU54NkNRWGZzOTRNaTUwWTBNUjhVek13Z05PSEd3MWs2MWtMU1R0Y2xRVExRcEFQTWRkZm40al9VdmlBY25FUk5hNldHOWdQcjlsTGozaFZsd1BlWFN1dWxsSy0yY2NxandsUXNsOVlGRlNTYTc5NERkTWxTMlJZcWc5X0FadVl5WW10WVE?oc=5","date":"2025-09-16","type":"trial","source":"BioPharma APAC","summary":"Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer - BioPharma APAC","headline":"Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPQS1fWXJ1R1lDdVpzdzZtQmxOdXB6SlhXNzB2NHdFSl82aGpxWlloME9wRUktX283N3o4dmw5bzVOdDZyRmwwVjM2dkNvTGJJWHYwcGpLeG4zYW5OOEM4RnRwTUhlajFwOUVGWml4VC04Rjc2Y0dKUlVIbUxoQ3BVZU1OMXpqYXBSSEdaZEgtdmt0RVctWFphRVp5ZDhpaWx5OGJrSGtWVFdSakxVQU9JWW8xVVprRmxCMEExMGlvdjUzWkh6Y2stdXhxbw?oc=5","date":"2025-08-26","type":"regulatory","source":"BioPharma APAC","summary":"Atossa Therapeutics Receives Approval To Open Clinical Study of AT-H201 in Australia - BioPharma APAC","headline":"Atossa Therapeutics Receives Approval To Open Clinical Study of AT-H201 in Australia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQa3BObUZ3amNyME9rR2xrT29MdEt4eVMweTU2VC0xcWRYb0duclQyZGtITHlLaTJKbl80ZkpfaTNfWjRDWWkzSFhlWkFfMGxDd3ZMVzl5TkVkaGtWTlV4NTEtU0pPT0x6TExTWGRMWDZZVE9OTjZHV2dyekRuUVh5UVIwa19wajlqemdjT1Q1YXlxVm84Si11OEQ0Y2o1aW5teV96YlZFU21tN3VsSkl2YmtjYnRMN3NqaWRpWlhKSQ?oc=5","date":"2025-08-04","type":"pipeline","source":"BioPharma APAC","summary":"Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma - BioPharma APAC","headline":"Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPT1dFblktZVVzVmoyNXVtdmxkRGVVY3Aya2lGU3N6TE1ubzc5ZTVqTl9sTGtTOGl0Y05JU3lwUl9NWEtjT1REVFdNRXVXQWFwZ3BnUkJsSmRwbEtDcF9IdTZ3ZGtRS1BuSWV5Z1BXbXd5cVhpYm1OV0p4Z01OSnJfZzR5dzUtdjNS?oc=5","date":"2024-03-11","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces: Pharma and biotech hires from February 2024 - pharmaphorum","headline":"Changing Faces: Pharma and biotech hires from February 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNNmxIemcwZTA3UjZoUXNZY0hpcVlFeENPNnhhRVV5amFZSG1kWXdsdWRPTzBGZG9faXZPbXk1Y2V4ME5NWTNJenZYSklnTlFudjdUVkx3VmhiS293dXlKZTAxYmFxbkhvODdiWDNsUmtsQ1RNRUd5aHVlNlczYXpsbUhvV05leTMwT0dxQ2hRdlZJaWFwSC1kbXRSWjdBT2hF?oc=5","date":"2023-09-27","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"6 Immuno-oncology Startups Attracting the Biggest VC Cash - Genetic Engineering and Biotechnology News","headline":"6 Immuno-oncology Startups Attracting the Biggest VC Cash","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}